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THE	CONTRIBUTION	OF	THE	RHO	PROTEIN	PATHWAY	TO	THE	TUMOUR	VASCULAR	DISRUPTING	
ACTION	OF	CA-4-P				
L.J.	Williams,	C.C.	Reyes,	C.	Kanthou,	G.M.	Tozer			
Tumour	Microcirculation	Group,	Academic	Unit	of	Surgical	Oncology,	The	University	of	Sheffield,	UK	
	
The	vascular	disrupting	agent,	combretastatin	A-4-	phosphate	(CA-4-P),	activates	GTPase	Rho	A	and	Rho	
kinase	in	endothelial	cells	in	vitro.	The	aim	was	to	investigate	whether	this	pathway	contributes	to	
vascular	shutdown	by	CA-4-P	in	vivo.	Colorectal	carcinoma	SW1222	cells	were	subcutaneously	implanted	
into	SCID	mice	and	treated	i.p.	with	CA-4-P	(30	or	100	mg/kg)	alone	or	in	combination	with	Y-27632	
(50mg/kg),	a	Rho	kinase	inhibitor.	One	or	3	hours	post-treatment,	mice	were	injected	with	fluorescein	
labelled	lectin	(i.v.)	for	endothelial	labelling	of	perfused	vessels,	and	tumours	removed	5	minutes	later	for	
subsequent	staining	for	endothelial	CD31.	Control	tumour	blood	vessels	had	38.5%	effective	perfusion	
(percentage	of	lectin	relative	to	CD31	staining).	CA-4-P	(100mg/kg)	significantly	reduced	perfusion	at	3	
hours	to	11.8%,	and	this	was	elevated	to	20.5%	with	Y-27632	pre-treatment.	These	data	suggest	that	Rho	
kinase	is	involved	in	the	mechanism	of	action	of	CA-4-P.	Another	inhibitor,	dibutyryl	cAMP	(dbcAMP),	
which	phosphorylates	and	inactivates	Rho	via	activating	protein	kinase	A,	was	also	used.	In	vitro,	dbcAMP	
blocked	CA-4-P	action	in	human	umbilical	endothelial	cells.	When	used	in	vivo,	dbcAMP	alone	
significantly	increased	perfusion	of	tumour	blood	vessels	relative	to	controls.	Further	studies	using	laser	
doppler	flowmetry	are	in	progress	to	confirm	this	response.	The	data	taken	together	imply	that	the	Rho	
protein	pathway	is	involved	in	the	relative	perfusion	of	tumour	vessels,	and	this	pathway	may	contribute	
to	the	vascular	disrupting	action	of	CA-4-P.		
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